Robert W. Baird Boosts DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $14.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target upped by investment analysts at Robert W. Baird from $12.00 to $14.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. Robert W. Baird’s price target would indicate a potential downside of 4.63% from the company’s previous close.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. cut their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Zacks Research cut DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a research report on Monday, November 10th. Barclays initiated coverage on DENTSPLY SIRONA in a research note on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Wednesday, January 21st. Finally, Barrington Research reaffirmed an “outperform” rating and set a $14.00 price target on shares of DENTSPLY SIRONA in a report on Monday, January 5th. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.00.

DENTSPLY SIRONA Stock Up 15.5%

XRAY opened at $14.68 on Friday. The firm’s 50 day simple moving average is $12.42 and its two-hundred day simple moving average is $12.48. The company has a market capitalization of $2.93 billion, a PE ratio of -4.89, a PEG ratio of 1.15 and a beta of 1.01. DENTSPLY SIRONA has a 1-year low of $9.85 and a 1-year high of $17.34. The company has a current ratio of 1.47, a quick ratio of 0.99 and a debt-to-equity ratio of 1.36.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The business had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 17.62%. The company’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts forecast that DENTSPLY SIRONA will post 1.84 EPS for the current year.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Gregory T. Lucier sold 82,200 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.50% of the stock is owned by insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

Hedge funds have recently modified their holdings of the stock. Mitsubishi UFJ Trust & Banking Corp grew its position in shares of DENTSPLY SIRONA by 1,836.7% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 105,938 shares of the medical instruments supplier’s stock valued at $1,344,000 after purchasing an additional 100,468 shares in the last quarter. Bank of Montreal Can boosted its stake in DENTSPLY SIRONA by 8.2% during the second quarter. Bank of Montreal Can now owns 352,524 shares of the medical instruments supplier’s stock valued at $5,598,000 after buying an additional 26,610 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in DENTSPLY SIRONA by 38.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 804,934 shares of the medical instruments supplier’s stock valued at $10,215,000 after buying an additional 223,339 shares in the last quarter. CWM LLC grew its holdings in DENTSPLY SIRONA by 84.3% during the 3rd quarter. CWM LLC now owns 420,470 shares of the medical instruments supplier’s stock valued at $5,336,000 after buying an additional 192,373 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its stake in DENTSPLY SIRONA by 42.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 348,989 shares of the medical instruments supplier’s stock worth $4,429,000 after acquiring an additional 104,588 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Key DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.